2016 annual financial data
Spero Therapeutics 2016 Operating cash flow margin
Direct answer
Operating cash flow margin was -8,644.48%.
Operating income was -33,221,000 USD and net income was -25,491,000 USD.
Operating cash flow was -28,959,000 USD.
Get free Spero Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 335,000 USD
- Operating income
- -33,221,000 USD
- Net income
- -25,491,000 USD
- Operating cash flow
- -28,959,000 USD